The most common of the KRAS mutations in non-small cell lung cancer (NSCLC) has been flagged as potentially targetable and may therefore help improve patient outcomes. A real-world study from the Thoracic Malignancies Cohort at Peter MacCallum Cancer Centre comprised 346 patients with metastatic or recurrent non-squamous NSCLC who had available KRAS mutation test results ...
KRAS mutation targeting offers better outcomes in NSCLC
By Mardi Chapman
21 Jul 2020